跳至主要内容
临床试验/NCT02502630
NCT02502630已完成不适用

CT-guided Percutaneous Microwave Ablation for Pulmonary Metastases From Colorectal Cancer

The First People's Hospital of Changzhou0 个研究点目标入组 32 人开始时间: 2010年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
32
主要终点
Overall Survival (OS)

研究概览

简要总结

(MWA) is the most recent development in the field of local ablative therapies. The aim of this study was to evaluate CT-guided percutaneous microwave (MW) ablation safety and efficacy in pulmonary metastases from colorectal cancer.

详细描述

From June 2010 to June 2015, 48 unresectable lesions in 32 patients with pulmonary metastases from colorectal cancer were selected for CT-guided microwave ablation. Patients were scheduled for a 1 and 3 month CT follow-up to evaluate lesion diameter.We retrospectively evaluated CT-guided percutaneous microwave (MW) ablation safety and efficacy in pulmonary metastases from colorectal cancer.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Unresectable pulmonary metastases from colorectal cancer.
  • diagnosis by CT, and confirmed by percutaneous puncture biopsy.
  • Age range 18-70 years old.
  • Eastern Cooperative Oncology Group performance status 0-
  • Life expectancy of more than 3 months.
  • Adequate organ function.

排除标准

  • Resectable lung metastases.
  • Life expectancy less than 3 months
  • Patients with cardiac pacemaker, cerebral aneurysm clips, implanted electronic instruments or other metal materials.
  • Coagulopathy with platelet count less than
  • Active infectious disease.
  • Age below 18 years.
  • Pregnancy of breastfeeding.

结局指标

主要结局

Overall Survival (OS)

时间窗: one year

次要结局

  • Treatment related adverse events(Eight weeks)

研究者

申办方类型
Other
责任方
Sponsor

相似试验